CD276 and renal cell adenocarcinoma: Currently, only a phase I study (NCT05293496) is evaluating vobramitamab duocarmazine (MCG018), an ADC directed against B7-H3 (also referred to as CD276), a member of the B7 family of immune regulatory proteins, expressed in numerous solid tumors, including RCC.